Rifampicin drug resistance and host immunity in tuberculosis: more than meets the eye |
| |
| Institution: | 1. Department of Molecular Microbiology, Washington University School of Medicine, St Louis, MO 63110, USA;2. Department of Microbiology, University of Chicago, Chicago, IL 60637, USA;1. Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, NY 10016, USA;2. Howard Hughes Medical Institute, New York University Grossman School of Medicine, New York, NY 10016, USA;1. Laboratory of Mucosal Immunology, The Rockefeller University, New York, NY, USA;2. Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA |
| |
| Abstract: | Tuberculosis (TB) is the leading cause of death due to an infectious agent, with more than 1.5 million deaths attributed to TB annually worldwide. The global dissemination of drug resistance across Mycobacterium tuberculosis (Mtb) strains, causative of TB, resulted in an estimated 450 000 cases of drug-resistant (DR) TB in 2021. Dysregulated immune responses have been observed in patients with multidrug resistant (MDR) TB, but the effects of drug resistance acquisition and impact on host immunity remain obscure. In this review, we compile studies that span aspects of altered host–pathogen interactions and highlight research that explores how drug resistance and immunity might intersect. Understanding the immune processes differentially induced during DR TB would aid the development of rational therapeutics and vaccines for patients with MDR TB. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
